- Preventive treatment with subcutaneous fremanezumab significantly reduced the number of migraine headache days compared with placebo in patients with episodic migraine in whom multiple medication classes had not previously failed.
- A monthly dosage and a single higher dosage designed for a quarterly dosing regimen were both effective at reducing migraine days.
Why this matters
- Preventive treatment is recommended for people who have at least 4 episodes per month of episodic migraine, which is the most common type of migraine.
- Randomized, placebo-controlled, parallel-group trial of 875 patients (fremanezumab monthly dosing, n=290; single higher dose, n=291; placebo, n=294) with episodic migraine.
- Patients underwent a screening visit, 12-week treatment period, and final evaluation at 12 weeks.
- Funding: Teva Pharmaceuticals.
- Mean monthly migraine days were 8.9 in the monthly dosing, 9.2 in single higher dose, and 9.1 in placebo groups.
- At 12 weeks, mean migraine days per month decreased to 4.9 days in monthly dosing group, 5.3 days in single higher dose, and 6.5 days in placebo groups.
- A statistically significant difference observed with monthly dosing vs placebo of –1.5 days (P<.001 and single higher dose vs placebo of days>
- Short follow-up duration.
Coauthored with Anand Ramanathan, PharmD